Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss

Stock Track02-19 20:24

Madrigal Pharmaceuticals' stock experienced a significant pre-market plunge, dropping 6.41% following the release of its fourth-quarter financial results.

The biopharmaceutical company reported Q4 revenue of $321.1 million, which exceeded consensus estimates of $312.49 million, driven by strong sales of its Rezdiffra treatment. However, the company posted a net loss of $58.58 million, with earnings per share of -$2.57, significantly missing analyst expectations which ranged from a loss of $0.40 to $0.90 per share.

Despite the revenue growth attributed to market penetration and disease awareness for Rezdiffra, the company's operating expenses surged to $380.69 million due to commercial activities and business development transactions, contributing to the larger-than-expected quarterly loss.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1161698493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 20:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1161698493","market":"sg","top_or_hot":-1,"title":"Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss","media":"Stock Track","content":"<p>Madrigal Pharmaceuticals' stock experienced a significant pre-market plunge, dropping 6.41% following the release of its fourth-quarter financial results.</p><p>The biopharmaceutical company reported Q4 revenue of $321.1 million, which exceeded consensus estimates of $312.49 million, driven by strong sales of its Rezdiffra treatment. However, the company posted a net loss of $58.58 million, with earnings per share of -$2.57, significantly missing analyst expectations which ranged from a loss of $0.40 to $0.90 per share.</p><p>Despite the revenue growth attributed to market penetration and disease awareness for Rezdiffra, the company's operating expenses surged to $380.69 million due to commercial activities and business development transactions, contributing to the larger-than-expected quarterly loss.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Madrigal Pharmaceuticals Plunges 6.41% in Pre-Market After Q4 Earnings Miss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-02-19 20:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Madrigal Pharmaceuticals' stock experienced a significant pre-market plunge, dropping 6.41% following the release of its fourth-quarter financial results.</p><p>The biopharmaceutical company reported Q4 revenue of $321.1 million, which exceeded consensus estimates of $312.49 million, driven by strong sales of its Rezdiffra treatment. However, the company posted a net loss of $58.58 million, with earnings per share of -$2.57, significantly missing analyst expectations which ranged from a loss of $0.40 to $0.90 per share.</p><p>Despite the revenue growth attributed to market penetration and disease awareness for Rezdiffra, the company's operating expenses surged to $380.69 million due to commercial activities and business development transactions, contributing to the larger-than-expected quarterly loss.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MDGL","symbol_name":"Madrigal Pharmaceuticals, Inc.","start_time":0,"source_url":"","article_id":"1161698493","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1161698493","pubTimestamp":1771503874,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Madrigal Pharmaceuticals' stock experienced a significant pre-market plunge, dropping 6.41% following the release of its fourth-quarter financial results.The biopharmaceutical company reported Q4...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MDGL":"Madrigal Pharmaceuticals, Inc."},"translate_title":"个股追踪|Madrigal Pharmaceuticals Q4财报未达预期盘前暴跌6.41%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDGL":1},"content_text":"Madrigal Pharmaceuticals' stock experienced a significant pre-market plunge, dropping 6.41% following the release of its fourth-quarter financial results.The biopharmaceutical company reported Q4 revenue of $321.1 million, which exceeded consensus estimates of $312.49 million, driven by strong sales of its Rezdiffra treatment. However, the company posted a net loss of $58.58 million, with earnings per share of -$2.57, significantly missing analyst expectations which ranged from a loss of $0.40 to $0.90 per share.Despite the revenue growth attributed to market penetration and disease awareness for Rezdiffra, the company's operating expenses surged to $380.69 million due to commercial activities and business development transactions, contributing to the larger-than-expected quarterly loss.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1161698493","isCrawlerRequest":true}